NuPathe Inc. announced on January 17, 2013 that the U.S. FDA had approved Zecuity (sumatriptan iontophoretic transdermal system) for the acute treatment of migraine with or without aura in adults. The product is a single-use, battery-powered patch that actively delivers sumatriptan through the skin, providing relief of both selleck migraine headache pain and migraine-related nausea. It is the first transdermal patch approved for the treatment of migraine. The company has also announced that it is planning for the market launch of the product by the end of 2013. 2014 should prove to be another lean year for new migraine products, as the only possible FDA approval would

be for inhaled dihydroergotamine. In January 2013, MAP Pharmaceuticals, Inc., the developer of dihydroergotamine inhalation aerosol Selumetinib manufacturer (Levadex), was acquired by Allergan, Inc. In April 2013, Allergan announced that the U.S. FDA had issued a Complete Response Letter to its New Drug Application for dihydroergotamine inhalation aerosol

for the acute treatment of migraine in adults. The company announced that it had met with the FDA to clarify their specific requirements for approval of the product. The company stated that it has agreed to these new requirements and that it planned to submit an amended file by the end of 2013. Based on these assumptions, possible FDA approval is expected in mid-2014. Merck initiated a large Phase 2 trial of MK-1602 entitled “A Dose-Finding Study of MK-1602 in the Treatment of Acute Migraine” (NCT01613248) in 2012. The study compared a 100-fold range of MK-1602 doses (ie, 1 to 100 mg) vs placebo. The planned 834 subject study was reportedly completed Liothyronine Sodium in late 2012. However, no results from this study have been disclosed, as of

late 2013. No further clinical development plans for MK-1602 have been announced by the company, and the drug no longer appears on the corporate listing of its products in development, as of late 2013. Bristol-Myers Squibb evaluated a small molecule CGRP antagonist (designated BMS-927711) in a large (n = 825) Phase 2 study entitled “Dose Ranging Study of a Drug for the Treatment of Acute Migraine” (NCT00216736). The objective of the study was to determine an effective and tolerable dose range of BMS-927711 for the acute treatment of migraine. In this randomized, double-blind, placebo-controlled, dose-ranging study, the subjects were randomized using an adaptive design to one of the following dose groups: BMS-927711 (10, 25, 75, 150, 300, or 600 mg), sumatriptan 100 mg (active comparator), or placebo. All subjects were treated for a single migraine attack. Pain freedom at 2 hours postdose, the primary end point, was significantly higher after doses of 75 mg (31%, P = .002), 150 mg (33%, P < .001), and 300 mg (30%, P = .002) BMS-927711, and after 100 mg (35%, P < .001) sumatriptan compared with placebo (15%).